bilhvax
Schistosomiasis, also known as snail fever, bilharzia, and Katayama fever is a neglected tropical disease caused by parasitic flatworms called schistosomes. It affects both humans and animals. It affects the urinary tract or the intestines. Symptoms include abdominal pain, diarrhea, bloody stool, or blood in the urine. Those who have been infected for a long time may experience liver damage, kidney failure, infertility, or bladder cancer. In children, schistosomiasis may cause poor growth and learning difficulties. Schistosomiasis belongs to the group of helminth infections. — Wikipedia
Clinical trial activity
1 trials · 2 clinical orgs · 0 marketing orgs
Earliest trial started Sep 1, 1998 (NCT01512277)
Timeline
1990s
- Jan 1, 1998
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- Schistosoma mansoniImmunity, active
Schistosoma mansoni immunity, active
Chemistry & pharmacology
Oral
No
Parenteral
No
Topical
No
Sources
- WikipediaSchistosomiasis ↗
Also known as
- bilhvax
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT01512277 | Phase 1 | Sep 1, 1998 | Institut National de la Santé Et de la Recherche Médicale, France, University of Lille |
Organizations
Research & Development (2)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Institut National de la Santé Et de la Recherche Médicale, France | Academic/Hospital | 1 | 0 | 1 | 1998 |
| University of Lille | Academic/Hospital | 1 | 1 | 1 | 1998 |